Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease
Objective History of cardiovascular diseases (CVDs) may influence the prognosis of patients hospitalised for COVID-19. We investigated whether patients with previous CVD have increased risk of death and major adverse cardiovascular event (MACE) when hospitalised for COVID-19.Methods We included 839...
Main Authors: | Antoine Poncet, Benjamin Assouline, Elena Tessitore, David Carballo, Nils Perrin, Cedric Follonier, Sebastian Carballo, François Girardin, Francois Mach |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-06-01
|
Series: | Open Heart |
Online Access: | https://openheart.bmj.com/content/8/1/e001526.full |
Similar Items
-
Association of Body Mass Index with Risk of Major Adverse Cardiovascular Events and Mortality in People with Diabetes
by: Dong Hun Lee, et al.
Published: (2018-03-01) -
Aspirin resistance and major adverse cardiovascular events (MACEs)
by: CHEN, YA-YU, et al.
Published: (2017) -
Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke
by: Wen-Jun Tu, et al.
Published: (2020-08-01) -
Angiopoietin-2, Renal Deterioration, Major Adverse Cardiovascular Events and All-Cause Mortality in Patients with Diabetic Nephropathy
by: Yi-Chun Tsai, et al.
Published: (2018-04-01) -
Angiopoietin-2 as a Prognostic Biomarker of Major Adverse Cardiovascular Events and All-Cause Mortality in Chronic Kidney Disease.
by: Yi-Chun Tsai, et al.
Published: (2015-01-01)